Content about Aliskiren

December 23, 2010

The Food and Drug Administration on Wednesday approved Novartis Pharmaceuticals’ Amturnide (aliskiren, amlodipine and hydrochlorothiazide) tablets for the treatment of high blood pressure, according to the pharma company.

EAST HANOVER, N.J. — The Food and Drug Administration on Wednesday approved Novartis Pharmaceuticals’ Amturnide (aliskiren, amlodipine and hydrochlorothiazide) tablets for the treatment of high blood pressure, according to the pharma company. 

Amturnide combines the only approved direct rennin inhibitor worldwide, Tekturna (aliskiren), with the widely used calcium channel blocker amlodipine and the diuretic hydrochlorothiazide (HCTZ).

August 26, 2010

The Food and Drug Administration has approved a single-pill combination of two drugs made by...

EAST HANOVER, N.J. The Food and Drug Administration has approved a single-pill combination of two drugs made by Novartis for treating high blood pressure, the Swiss drug maker said Friday.

 

The FDA approved Tekamlo (aliskiren and amlodipine besylate) tablets, which combine Tekturna (aliskiren) with amlodipine, a channel blocker available as a generic. The drug is approved for treating patients who are likely to need multiple drugs to lower their blood pressure or as a replacement for patients who can’t control it using one of the drugs alone.